GSK PLC Raises Guidance After RSV Vaccine Lifts Earnings

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.

https://www.wsj.com/business/earnings/gsk-plc-raises-guidance-after-rsv-vaccine-lifts-earnings-ca7bd091GSK PLC raised its guidance after third-quarter net profit rose mainly due to the U.S. launch of its Arexvy vaccine, although it missed analysts’ forecasts. The British pharmaceutical giant said Wednesday that net profit from continuing operations for the third quarter was 1.46 billion pounds , boosted by the vaccine for respiratory syncytial virus, or RSV, compared with GBP759 million a year earlier and a company-compiled consensus of GBP1.87 billion.This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law.

ประเทศไทย ข่าวล่าสุด, ประเทศไทย หัวข้อข่าว

Similar News:คุณยังสามารถอ่านข่าวที่คล้ายกันนี้ซึ่งเรารวบรวมจากแหล่งข่าวอื่น ๆ ได้

Amgen’s stock jumps premarket after earnings beat and company again raises guidanceCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
แหล่ง: MarketWatch - 🏆 3. / 97 อ่านเพิ่มเติม »

Drug Stocks Keep Falling on Earnings. It Could Be a Long Week.Companies scheduled to report their results include Pfizer, GSK, Eli Lilly, and Novo Nordisk.
แหล่ง: MarketWatch - 🏆 3. / 97 อ่านเพิ่มเติม »